AN2 Therapeutics Overview
Valuation check: ANTX's ROE is -42.26%, below the sector sector average of -4.47%.
Get informed when a big investor buys or sells
+ Follow-42.26%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
AN2 Therapeutics (ANTX) currently reports a ROE of -42.26%. That is below the sector sector average of -4.47%. Use the charts on this page to explore AN2 Therapeutics's ROE history and peer comparisons.
AN2 Therapeutics's ROE of -42.26% is lower than the its sector sector average of -4.47%. That is roughly 845.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but AN2 Therapeutics's current -42.26% should be judged against industry norms (sector average: -4.47%) and against ANTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -42.26%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.47%. From there, open related valuation or income-statement pages for AN2 Therapeutics, and consider following ANTX for alerts when major investors trade the stock.
